HANSOH PHARMA(03692) 中国经济网·2025-04-10 04:12Core Insights - The 34th Asia-Pacific Association for the Study of the Liver (APASL 2025) conference highlighted the academic achievements of Hansoh Pharmaceutical's oral antiviral drug, TMF (Amitriptyline), which is the first original research drug for hepatitis B in China [1][2] - TMF demonstrated significant efficacy in chronic hepatitis B patients, with a 95% cumulative HBV DNA suppression rate and a 68% HBeAg seroconversion rate over five years, the highest among current NAs [1] - The drug's safety profile remained stable, with no new drug-related adverse events reported during the study period [1] Group 1 - TMF's Phase IV study showed sustained benefits for chronic hepatitis B patients, particularly in virological response and HBeAg seroconversion [1] - The cumulative incidence of virological resistance after five years of treatment with TMF was 0% [1] - The immunological mechanism study indicated TMF's potential to modulate T cell responses and reduce viral load, contributing to its antiviral efficacy [1] Group 2 - Over 20 additional studies related to TMF were presented, covering its application in various subpopulations, including the elderly, pregnant women, and patients with liver cirrhosis and liver cancer [2] - A systematic review and network meta-analysis indicated TMF's superiority in ALT normalization and delaying liver fibrosis progression compared to other new-generation NAs [2] - TMF was shown to have good maternal-fetal safety and efficacy in treating hepatitis B in pregnant women, successfully preventing HBV mother-to-child transmission [2]